A. N. Al Balawi et al., "Perceptions of medicinal herbal products during the COVID-19 pandemic period among Saudi patients: a cross-sectional study," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 1, pp. 497–506, 2024, https://doi.org/10.1007/s00210-023-02610-6

D. H. Alamdari et al., "Methylene blue for treatment of hospitalized COVID-19 patients, randomized, controlled, open-label clinical trial, Phase 3," Aristotle Biomedical Journal, vol. 3, no. 2, pp. 1–7, 2021, https://doi.org/10.24875/ric.21000028.

Al-Tawfiq JA, Temsah M-H (2023) Perspective on the challenges of COVID-19 facing healthcare workers. Infection 51(2):541–544. https://doi.org/10.1007/s15010-022-01882-z

Article  CAS  PubMed  Google Scholar 

Aslan A, Aslan C, Zolbanin NM, Jafari R (2021) Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia 13(1):14. https://doi.org/10.1186/s41479-021-00092-9

Article  PubMed  PubMed Central  Google Scholar 

Bellani G et al (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315(8):788–800. https://doi.org/10.1001/jama.2016.0291

Article  CAS  PubMed  Google Scholar 

Bojadzic D, Alcazar O, Buchwald P (2021) Methylene blue inhibits the SARS-CoV-2 spike–ACE2 protein-protein interaction–a mechanism that can contribute to its antiviral activity against COVID-19. Front Pharmacol 11:600372. https://doi.org/10.3389/fphar.2020.600372

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bong C-L, Brasher C, Chikumba E, McDougall R, Mellin-Olsen J, Enright A (2020) The COVID-19 pandemic: effects on low-and middle-income countries. Anesth Analg 131(1):86–92. https://doi.org/10.1213/ANE.0000000000004846

Article  CAS  PubMed  Google Scholar 

Chuang S-T et al (2022) Methylene blue is a nonspecific protein–protein interaction inhibitor with potential for repurposing as an antiviral for COVID-19. Pharmaceuticals 15(5):621. https://doi.org/10.3390/ph15050621

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G (2021) Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed Pharmacother 142:112023. https://doi.org/10.1016/j.biopha.2021.112023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan E et al (2020) COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med 8(8):816–821. https://doi.org/10.1016/S2213-2600(20)30304-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

R. Filip, R. Gheorghita Puscaselu, L. Anchidin-Norocel, M. Dimian, and W. K. Savage, "Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems," Journal of personalized medicine, vol. 12, no. 8, p. 1295, 2022, https://doi.org/10.3390/jpm12081295.

Gattinoni L, Chiumello D, Covid SR (2020) pneumonia: ARDS or not? Crit Care 24(1):154. https://doi.org/10.1186/s13054-020-02880-z

Article  PubMed  PubMed Central  Google Scholar 

Gendrot M et al (2020) Methylene blue inhibits replication of SARS-CoV-2 in vitro. Int J Antimicrob Agents 56(6):106202. https://doi.org/10.1016/j.ijantimicag.2020.106202

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gendrot M et al (2021) In vitro evaluation of the antiviral activity of methylene blue alone or in combination against SARS-CoV-2. J Clin Med 10(14):3007. https://doi.org/10.3390/jcm10143007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghahestani SM, Shahab E, Karimi S, Madani MH (2020) Methylene blue may have a role in the treatment of COVID-19. Med Hypotheses 144:110163. https://doi.org/10.1016/j.mehy.2020.110163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghodke BA, Ghodke A, Mahadik V, Thorat P (2022) Methylene blue treatment for moderate-to-severe cases of acute respiratory syndrome due to COVID-19 infection: clinical outcomes—a prospective study. MGM Journal of Medical Sciences 9(1):25–32. https://doi.org/10.4103/mgmj.mgmj_18_22

Article  Google Scholar 

Gibson PG, Qin L, Puah SH (2020) COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J Aust 213(2):54. https://doi.org/10.5694/mja2.50674

Article  PubMed  PubMed Central  Google Scholar 

Ginimuge PR, Jyothi SD (2010) Methylene blue: revisited. J Anaesthesiol Clin Pharmacol 26(4):517–520

Article  PubMed  PubMed Central  Google Scholar 

Gopalan HS, Misra A (2020) COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India. Diabetes Metab Syndr 14(5):757–759. https://doi.org/10.1016/j.dsx.2020.05.041

Article  PubMed  PubMed Central  Google Scholar 

Gordon DE et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583(7816):459–468. https://doi.org/10.1038/s41586-020-2286-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamidi-Alamdari D et al (2021) “Methylene Blue for Treatment of Hospitalized COVID-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2,” (in eng). Rev Invest Clin 73(3):190–198. https://doi.org/10.24875/ric.21000028

Article  CAS  PubMed  Google Scholar 

Heching M, Lev S, Shitenberg D, Dicker D, Kramer MR (2021) Surfactant for the Treatment of ARDS in a Patient With COVID-19. Chest 160(1):9–12. https://doi.org/10.1016/j.chest.2021.01.028

Article  CAS  Google Scholar 

M. Henry, M. Summa, L. Patrick, and L. Schwartz, "A cohort of cancer patients with no reported cases of SARS-CoV-2 infection: the possible preventive role of Methylene Blue," Substantia, vol. 4, no. 1, pp. 1–11, 2020, https://doi.org/10.13128/Substantia-888.

Hepburn J, Williams-Lockhart S, Bensadoun RJ, Hanna R (2022) A novel approach of combining methylene blue photodynamic inactivation, photobiomodulation and oral ingested methylene blue in COVID-19 management: A pilot clinical study with 12-month follow-up. Antioxidants 11(11):2211

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Horie et al., "Emerging pharmacological therapies for ARDS: COVID-19 and beyond," Intensive Care Medicine, vol. 46, no. 12, pp. 2265–2283, 2020/12/01 2020, https://doi.org/10.1007/s00134-020-06141-z.

X. Huang, W. Yan, Z. Chen, and Y. Qian, "Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials," BMJ open, vol. 14, no. 1, pp. 1–7, 2024, https://doi.org/10.1136/2Fbmjopen-2023-080065.

Jack Clifton, II and J. B. Leikin, "Methylene blue," American journal of therapeutics, vol. 10, no. 4, pp. 289–291, 2003.

N. Jebril, "World Health Organization declared a pandemic public health menace: a systematic review of the coronavirus disease 2019 “COVID-19”," Available at SSRN 3566298, 2020, https://www.psychosocial.com/article/PR290311/25748/.

N. Mahale et al., "Intravenous methylene blue as a rescue therapy in the management of refractory hypoxia in COVID-19 ARDS patients: a case series," Indian Journal of Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine, vol. 25, no. 8, p. 934, 2021, https://doi.org/10.5005/2Fjp-journals-10071-23905.

Marini JJ, Gattinoni L (2020) Management of COVID-19 respiratory distress. JAMA 323(22):2329–2330. https://doi.org/10.1001/jama.2020.6825

Article  PubMed  Google Scholar 

M. G. Matera, P. Rogliani, L. Calzetta, and M. Cazzola, "Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review," Respiratory Medicine, vol. 171, p. 106114, 2020/09/01/ 2020, https://doi.org/10.1016/j.rmed.2020.106114.

Matthay MA, Aldrich JM, Gotts JE (2020) Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med 8(5):433–434. https://doi.org/10.1016/S2213-2600(20)30127-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyerowitz-Katz G, Merone L (2020) A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis 101:138–148. https://doi.org/10.1016/j.ijid.2020.09.1464

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nedu M-E, Tertis M, Cristea C, Georgescu AV (2020) Comparative study regarding the properties of methylene blue and proflavine and their optimal concentrations for in vitro and in vivo applications. Diagnostics 10(4):223. https://doi.org/10.3390/diagnostics10040223

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfab F, Buelow-Johansen B, Alber D, Kriner M, Kornmann O, Stuermer M (2023) Reduction of SARS-CoV-2 viral load in exhaled air by antiseptic chewing gum: a pilot trial. Infection 51(4):881–885.